ClinicalTrials.gg
CompletedNCT02736240Updated Oct 14, 2020

Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

A Phase 3 interventional study of 7-valent pneumococcal conjugate vaccine and 13-valent pneumococcal polysaccharide conjugate vaccine in Diseases Caused by Streptococcus Pneumoniae Serotypes, sponsored by Walvax Biotechnology Co., Ltd.. Completed. Open to participants aged 2 Months to 71 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-14.

Sponsored by Walvax Biotechnology Co., Ltd. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,760
Allocation
Randomized
Ages
2 Months to 71 Months
Sex
All
01

Study summary

The purpose of this study is to investigate and valuate the immunogenicity and safety of the 13-valent pneumococcal polysaccharide conjugate vaccine in 2-71 months old healthy infants and toddlers (the youngest could be 6 weeks old)

02

Conditions studied

  • Diseases Caused by Streptococcus Pneumoniae Serotypes
03

In context

Lead sponsor

Walvax Biotechnology Co., Ltd. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months to 71 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 2-71 months (the youngest could be 6 weeks old) infants or toddlers which are positively healthy based on the medical history, the physical examination and the judgment of the investigator;
  • The statutory guardian (or the consignor) of the subject agree his/her child participate in the study, and is willing to sign the form;
  • The subject and his/her statutory guardians (or the consignor) are able to comply with the requests of the clinical study protocol;
  • Never be immunized with any pneumococcus vaccine, and didn't get immunization with any other preventive product in the past 10 days (didn't get immunized with attenuated in the past 14 days);
  • The auxillary temperature ≤37℃.

Exclusion criteria

Exclusion Criteria:

  • Has already been immunized with pneumococcus vaccine no matter it is experimental or marketed;
  • With the history of invasive disease caused by streptococcus pneumonia by culture;
  • With the history of serious allergy to any vaccine or drug, has got fever higher than 39℃ related to immunization with preventive biological product;
  • Infant that the birth weight is lighter than 2.5 kg;
  • With the history or the family history of seizure, epilepsy, cerebropathy and psychosis ;
  • Infant with the abnormal labor (difficult labor, deliver with apparatus) or with the history of asphyxia or nervous damage;
  • With the history of thrombocytopenia or other coagulation disorders by definite diagnosis;
  • Infant or toddler with pathological jaundice by diagnosis;
  • Be known with or suspected with immunological dysfunction, including therapy (radiotherapy, chemotherapy, hormone, antimetabolites, cytotoxic drug), infection etc. ;
  • Be known with serious congenital malformation or serious chronic disease; suffer from congenital malformation or be diagnosed with serious chronic disease (eg. Down syndrome, diabetes mellitus, sickle cell anemia or nervous disease, Guillain-Barre syndrome);
  • Be known with or suspected with diseases including: disease of respiratory system, acute infection or the active period of chronic disease, serious cardiovascular disease, hepatic-nephrotic disease, malignant tumor, skin disease;
  • Has taken blood product or globulin (the immune globulin is allowed);
  • Be participating in other clinical trials;
  • Any other situation which is considered to influence the evaluation of the study by investigators .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2,760 participants (actual)

Study arms

  • Active comparator
    Control Arm

    7-valent pneumococcal conjugate vaccine

    Biological: 7-valent pneumococcal conjugate vaccine

  • Experimental
    Test Arm

    13-valent pneumococcal conjugate vaccine

    Biological: 13-valent pneumococcal polysaccharide conjugate vaccine

06

What researchers measure

Primary outcomes

  1. positive rate after infant doses

    the rate of the immunoglobulin G ≥0.35μg/ml after infant doses

    Time frame: 30 days after infant doses

  2. GMC after infant doses

    geometrical mean concentration of immunoglobulin G after infant doses

    Time frame: 30 days after infant doses

  3. positive rate after booster dose

    the rate of the immunoglobulin G ≥0.35μg/ml after booster dose

    Time frame: 30 days after booster dose

  4. GMC after booster dose

    geometrical mean concentration of immunoglobulin G after booster dose

    Time frame: 30 days after booster dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Chen JJ, Yuan L, Huang Z, Shi NM, Zhao YL, Xia SL, Li GH, Li RC, Li YP, Yang SY, Xia JL. Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China. BMJ Open. 2016 Oct 19;6(10):e012488. doi: 10.1136/bmjopen-2016-012488. PubMed 27798013 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2016 to primary completion in Dec 2017, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2016
First posted
Apr 13, 2016
StartActual
Apr 8, 2016
Primary completionActual
Dec 3, 2017
CompletionActual
Dec 3, 2017
Last update
Oct 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02736240
Lead sponsor
Walvax Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 13, 2016
Start date
Apr 8, 2016
Primary completion
Dec 3, 2017
Completion
Dec 3, 2017
Last update
Oct 14, 2020

Study contacts

Nianmin Shi
principal investigator · Beijing Chaoyang disease control and prevention center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion